Research Paper Volume 10, Issue 5 pp 973—987
Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma
- 1 Department of Preventive Medicine, School of Health Sciences, Wuhan University, Wuhan, Hubei 430071, P.R. China
- 2 Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
- 3 Department of Occupational and Environmental Health, School of Health Sciences, Wuhan University, Wuhan, Hubei 430071, P.R. China
- 4 Wuhan Hospital for the Prevention and Treatment of Occupational Diseases, Wuhan, Hubei 430022, P.R. China
- 5 Department of Oncology, Wuhan Pu-Ai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430034, P.R. China
- 6 Hubei Provincial Key Laboratory for Applied Toxicology (Hubei Provincial Academy for Preventive Medicine), Wuhan, Hubei 430079, P.R. China
- 7 Department of Infectious Diseases, Wuhan Medical Treatment Center, Wuhan, Hubei 430023, P.R. China
- 8 Department of Oncology, ZhongNan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
- 9 Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei 430021, P.R. China
- 10 Department of Pathology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China
- 11 Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Received: March 22, 2018 Accepted: April 28, 2018 Published: May 11, 2018
https://doi.org/10.18632/aging.101441How to Cite
Abstract
E2F is a group of genes that encode a family of transcription factors (TFs) in higher eukaryotes and participate in cell cycle regulation and DNA synthesis in mammalian cells. Evidence from cell lines, mouse models, and human tissues indicates that TFs are implicated in lung cancer (LC) tumorigenesis. However, the diverse expression patterns and prognostic values of eight E2Fs have yet to be elucidated. In the current study, we examined the transcriptional and survival data of E2Fs in patients with LC from ONCOMINE, GEPIA, Kaplan–Meier Plotter, and cBioPortal databases. We found that the expression levels of E2F1/2/3/5/6/7/8 were higher in lung adenocarcinoma and squamous cell lung carcinoma tissues than in lung tissues, whereas the expression level of E2F4 was lower in the former than in the latter. The expression levels of E2F2/4/5/7/8 were correlated with advanced tumor stage. Survival analysis using the Kaplan–Meier Plotter database revealed that the high transcription levels of E2F1/2/4/5/7/8 were associated with low relapse-free survival (RFS) in all of the patients with LC. Conversely, high E2F3/6 levels predicted high RFS in these patients. This study implied that E2F3/6/7 are potential targets of precision therapy for patients with LC and that E2F1/2/4/5/8 are new biomarkers for the prognosis of LC.